Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $25.3 million.

  • Amphastar Pharmaceuticals' Change in Accured Expenses rose 279.94% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.2 million, marking a year-over-year decrease of 3077.0%. This contributed to the annual value of $63.6 million for FY2024, which is 38019.19% up from last year.
  • Amphastar Pharmaceuticals' Change in Accured Expenses amounted to $25.3 million in Q3 2025, which was up 279.94% from -$4.9 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' Change in Accured Expenses' 5-year high stood at $25.3 million during Q3 2025, with a 5-year trough of -$14.7 million in Q3 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Change in Accured Expenses value was $3.7 million (recorded in 2022), while the average stood at $6.2 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 116226.77% in 2022, then soared by 280337.84% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$1.1 million in 2021, then tumbled by 1162.27% to -$13.6 million in 2022, then skyrocketed by 75.06% to -$3.4 million in 2023, then skyrocketed by 162.34% to $2.1 million in 2024, then surged by 1099.72% to $25.3 million in 2025.
  • Its Change in Accured Expenses was $25.3 million in Q3 2025, compared to -$4.9 million in Q2 2025 and $17.6 million in Q1 2025.